IRVINE, Calif.--(BUSINESS WIRE)--Mar. 22, 2016--
Masimo
(NASDAQ: MASI) announced today that it supports Larry Ellison’s
announcement about Raymond Moore’s resignation as CEO of Indian Wells.
Masimo has been a Premier Sponsor of the BNP Paribas Open and presenting
sponsor for the McEnroe Challenge for Charity for several years.
“Women’s tennis is just as fun and exciting to watch as the men’s game.
Mr. Moore’s disturbing comments regarding WTA and female tennis players
shocked us,” said Joe Kiani, Founder and CEO of Masimo. “BNP Paribas
Open Tennis is the best tennis I have seen. With the swift move to
disassociate this great event from Mr. Moore’s comments, we are once
again proud to be associated with this great event. We appreciate all
that Mr. Larry Ellison has brought to the game of tennis. And, we are
even more appreciative of the players who make tennis great, from Serena
Williams and Victoria Azarenka to Roger Federer and Rafael Nadal. We are
also excited about some of the up and coming players like Coco
Vandeweghe and Andrea Hlavackova, whom we are proudly sponsoring. With
this announcement, we look forward to supporting BNP Paribas Open in
2017.”
BNP Paribas Open is an annual tennis tournament held in Indian Wells,
California. The tournament is a Masters 1000 event on the men’s tour and
a Premier Mandatory event on the women’s tour. This is one of the best
attended tennis tournament with over 450,000 visitors during the event
and 18,000,000 viewers.
@MasimoInnovates
| #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. The benefits of Masimo SET® have
been proven in more than 100 independent and objective studies and it is
estimated to be used on more than 100 million patients in leading
hospitals and other healthcare settings around the world. In 2005,
Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously could only be measured invasively, including total hemoglobin
(SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and more recently, Pleth Variability Index
(PVI®) and Oxygen Reserve Index (ORI™), in addition to SpO2, pulse rate,
and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive
open architecture patient monitoring and connectivity platform designed
to speed the pace of innovation and reduce the cost of care. Masimo is
also taking an active leadership role in mHealth with products such as
the Radius-7™ wearable patient monitor and the MightySat™ fingertip
pulse oximeter. Additional information about Masimo and its products may
be found at www.masimo.com.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo technology. These forward-looking statements are
based on current expectations about future events affecting us and are
subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our
actual results to differ materially and adversely from those expressed
in our forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to our
belief that Masimo's unique noninvasive measurement technologies
contribute to positive clinical outcomes and patient safety; risks
related to our belief that Masimo noninvasive medical breakthroughs
provide cost-effective solutions with comparable accuracy and unique
advantages, including: immediate and continuous results that enable
earlier treatment without causing invasive trauma in all patients and in
every clinical situation; as well as other factors discussed in the
"Risk Factors" section of our most recent reports filed with the
Securities and Exchange Commission (“SEC”), which may be obtained for
free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160322006155/en/
Source: Masimo
Masimo
Irene Paigah
858-859-7001
irenep@masimo.com